一种针对结核病的Toll样受体2导向融合蛋白疫苗。
A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis.
作者信息
Wang Baolin, Henao-Tamayo Marcela, Harton Marisa, Ordway Diane, Shanley Crystal, Basaraba Randall J, Orme Ian M
机构信息
Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
出版信息
Clin Vaccine Immunol. 2007 Jul;14(7):902-6. doi: 10.1128/CVI.00077-07.
Abstract
A fusion protein designated CSU-F36 was constructed that consisted of acylated Rv1411, a potent Toll-like receptor-2 agonist, fused to ESAT-6, a well-characterized immunogenic protein from Mycobacterium tuberculosis. The CSU-F36 fusion protein strongly induced interleukin 12 secretion from macrophages and induced the increased accumulation of CD4 T cells capable of secreting gamma interferon in the lungs of infected mice. These mice were significantly protected from low-dose aerosol challenge with M. tuberculosis, even with CSU-F36 delivered in a simple depot material. This "natural adjuvant"-containing system could potentially bypass the need for more expensive TH1-inducing adjuvants and could be applied to many mycobacterial proteins to provide effective and cheap new vaccines against tuberculosis.
摘要
构建了一种名为CSU-F36的融合蛋白，它由酰化的Rv1411（一种有效的Toll样受体2激动剂）与ESAT-6（一种来自结核分枝杆菌的特征明确的免疫原性蛋白）融合而成。CSU-F36融合蛋白强烈诱导巨噬细胞分泌白细胞介素12，并诱导感染小鼠肺部能够分泌γ干扰素的CD4 T细胞积累增加。这些小鼠在接受低剂量结核分枝杆菌气溶胶攻击时得到了显著保护，即使CSU-F36是通过一种简单的长效材料递送的。这种含有“天然佐剂”的系统可能无需使用更昂贵的TH1诱导佐剂，并且可应用于多种分枝杆菌蛋白，以提供有效且廉价的新型抗结核疫苗。
相似文献
1
A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis.
Clin Vaccine Immunol. 2007 Jul;14(7):902-6. doi: 10.1128/CVI.00077-07.
2
Enhanced effect of BCG vaccine against pulmonary Mycobacterium tuberculosis infection in mice with lung Th17 response to mycobacterial heparin-binding hemagglutinin adhesin antigen.
Microbiol Immunol. 2015 Dec;59(12):735-43. doi: 10.1111/1348-0421.12340.
3
Rv2299c, a novel dendritic cell-activating antigen of Mycobacterium tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable protection against the hypervirulent strain HN878 in mice.
Oncotarget. 2017 Mar 21;8(12):19947-19967. doi: 10.18632/oncotarget.15256.
4
Synthetic protein conjugate vaccines provide protection against in mice.
Proc Natl Acad Sci U S A. 2021 Jan 26;118(4). doi: 10.1073/pnas.2013730118.
5
GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.
Clin Vaccine Immunol. 2017 Dec 5;24(12). doi: 10.1128/CVI.00245-17. Print 2017 Dec.
6
Protective efficacy of a recombinant BCG secreting antigen 85B/Rv3425 fusion protein against Mycobacterium tuberculosis infection in mice.
Hum Vaccin Immunother. 2012 Dec 1;8(12):1869-74. doi: 10.4161/hv.21817. Epub 2012 Aug 21.
7
Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6.
J Microbiol Immunol Infect. 2014 Feb;47(1):48-56. doi: 10.1016/j.jmii.2012.11.005. Epub 2013 Jan 26.
8
TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines.
Vaccine. 2013 Sep 13;31(40):4322-9. doi: 10.1016/j.vaccine.2013.07.022. Epub 2013 Jul 20.
9
Heterologous Boost Following Reduces the Late Persistent, Rather Than the Early Stage of Intranasal Tuberculosis Challenge Infection.
Front Immunol. 2018 Oct 30;9:2439. doi: 10.3389/fimmu.2018.02439. eCollection 2018.
10
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
J Immunol. 2005 Mar 15;174(6):3570-9. doi: 10.4049/jimmunol.174.6.3570.
引用本文的文献
1
Proteome Profile Changes Induced by Heterologous Overexpression of -Derived Antigens PstS-1 (Rv0934) and Ag85B (Rv1886c) in .
Biomolecules. 2022 Dec 8;12(12):1836. doi: 10.3390/biom12121836.
2
GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.
Clin Vaccine Immunol. 2017 Dec 5;24(12). doi: 10.1128/CVI.00245-17. Print 2017 Dec.
3
Mycobacterium tuberculosis Rv3628 drives Th1-type T cell immunity via TLR2-mediated activation of dendritic cells and displays vaccine potential against the hyper-virulent Beijing K strain.
Oncotarget. 2016 May 3;7(18):24962-82. doi: 10.18632/oncotarget.8771.
4
Dendritic cell targeted vaccines: Recent progresses and challenges.
Hum Vaccin Immunother. 2016 Mar 3;12(3):612-22. doi: 10.1080/21645515.2015.1105415.
5
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.
Clin Transl Immunology. 2015 Apr 10;4(4):e35. doi: 10.1038/cti.2015.6. eCollection 2015 Apr.
6
Vaccines for TB: Lessons from the Past Translating into Future Potentials.
J Immunol Res. 2015;2015:916780. doi: 10.1155/2015/916780. Epub 2015 Jun 3.
7
Dendritic cell-targeted vaccines--hope or hype?
Nat Rev Immunol. 2014 Oct;14(10):705-11. doi: 10.1038/nri3727. Epub 2014 Sep 5.
8
Targeting TLR2 for vaccine development.
J Immunol Res. 2014;2014:619410. doi: 10.1155/2014/619410. Epub 2014 Jun 26.
9
Role of Fused Mycobacterium tuberculosis Immunogens and Adjuvants in Modern Tuberculosis Vaccines.
Front Immunol. 2014 Apr 23;5:188. doi: 10.3389/fimmu.2014.00188. eCollection 2014.
10
TLR2 engagement on CD4(+) T cells enhances effector functions and protective responses to Mycobacterium tuberculosis.
Eur J Immunol. 2014 May;44(5):1410-21. doi: 10.1002/eji.201344100. Epub 2014 Mar 14.
本文引用的文献
1
Aggravated infection in mice co-administered with Mycobacterium tuberculosis and the 27-kDa lipoprotein.
Microbes Infect. 2006 Jun;8(7):1750-7. doi: 10.1016/j.micinf.2006.02.011. Epub 2006 Apr 24.
2
Pseudo-rationale design of efficient TB vaccines: lesson from the mycobacterial 27-kDa lipoprotein.
Tuberculosis (Edinb). 2006 May-Jul;86(3-4):225-35. doi: 10.1016/j.tube.2006.01.012. Epub 2006 Mar 3.
3
Preclinical testing of new vaccines for tuberculosis: a comprehensive review.
Vaccine. 2006 Jan 9;24(1):2-19. doi: 10.1016/j.vaccine.2005.07.078. Epub 2005 Aug 8.
4
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.
Infect Immun. 2004 Nov;72(11):6622-32. doi: 10.1128/IAI.72.11.6622-6632.2004.
5
A limited antigen-specific cellular response is sufficient for the early control of Mycobacterium tuberculosis in the lung but is insufficient for long-term survival.
Infect Immun. 2004 Jul;72(7):3759-68. doi: 10.1128/IAI.72.7.3759-3768.2004.
6
Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein.
J Immunol. 2004 Jun 15;172(12):7618-28. doi: 10.4049/jimmunol.172.12.7618.
7
The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection.
Infect Immun. 2003 Jun;71(6):3146-54. doi: 10.1128/IAI.71.6.3146-3154.2003.
8
The TB epidemic from 1992 to 2002.
Tuberculosis (Edinb). 2003;83(1-3):4-14. doi: 10.1016/s1472-9792(02)00071-9.
9
Dynamics of gamma interferon, interleukin-12 (IL-12), IL-10, and transforming growth factor beta mRNA expression in primary Mycobacterium bovis BCG infection in guinea pigs measured by a real-time fluorogenic reverse transcription-PCR assay.
Infect Immun. 2002 Dec;70(12):6614-20. doi: 10.1128/IAI.70.12.6614-6620.2002.
10
Control of Mycobacterium tuberculosis through mammalian Toll-like receptors.
Curr Opin Immunol. 2002 Aug;14(4):452-7. doi: 10.1016/s0952-7915(02)00355-2.
Zotero 插件